Figure 2
Risk markers in relation to overall survival. Both existing markers and validated novel combinations are shown. For novel combinations, the results shown represent the validation. For confirmation of existing markers, no discovery/validation split is required and results shown are based on all available data. In the left panel, existing markers and novel combinations (denoted by an asterisk) are listed. For each marker, the number of risk groups (n. groups) and number of available patients are given (number [n.] of patients). Markers are sorted by the number of risk groups. In the center panel, the hazard ratios are shown (open circles), with Bonferroni adjusted 95% CIs (indicated by 2 lines and closed circles). For coherent notation, hazard ratios are expressed relative to the lowest risk group. Every additional risk group results in an extra hazard ratio. For instance, for the novel combination EMC92-ISS, 4 risk groups result in 3 hazard ratios, as indicated in the text and supplemental Table 2A (intermediate-low risk relative to low risk: hazard ratio, 2.6; 95% CI, 1.6-4.5); intermediate-high risk relative to low risk: hazard ratio, 3.2 (95% CI, 1.9-5.4); and high risk relative to low risk: hazard ratio, 6.9 [95% CI, 4.1-12]). In the right panel, a plus sign indicates whether a data set could be used for the analysis of a specific marker or combination (for details of available data, see Table 1 and supplemental Figure 1). For the EMC92-ISS combination, the following datasets could be used: APEX, MRC-IX, TT2, and TT3.

Risk markers in relation to overall survival. Both existing markers and validated novel combinations are shown. For novel combinations, the results shown represent the validation. For confirmation of existing markers, no discovery/validation split is required and results shown are based on all available data. In the left panel, existing markers and novel combinations (denoted by an asterisk) are listed. For each marker, the number of risk groups (n. groups) and number of available patients are given (number [n.] of patients). Markers are sorted by the number of risk groups. In the center panel, the hazard ratios are shown (open circles), with Bonferroni adjusted 95% CIs (indicated by 2 lines and closed circles). For coherent notation, hazard ratios are expressed relative to the lowest risk group. Every additional risk group results in an extra hazard ratio. For instance, for the novel combination EMC92-ISS, 4 risk groups result in 3 hazard ratios, as indicated in the text and supplemental Table 2A (intermediate-low risk relative to low risk: hazard ratio, 2.6; 95% CI, 1.6-4.5); intermediate-high risk relative to low risk: hazard ratio, 3.2 (95% CI, 1.9-5.4); and high risk relative to low risk: hazard ratio, 6.9 [95% CI, 4.1-12]). In the right panel, a plus sign indicates whether a data set could be used for the analysis of a specific marker or combination (for details of available data, see Table 1 and supplemental Figure 1). For the EMC92-ISS combination, the following datasets could be used: APEX, MRC-IX, TT2, and TT3.

Close Modal

or Create an Account

Close Modal
Close Modal